Chapter 11 Systemic Inflammatory Response Syndrome

  1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20(6):864–874, 1992.
  2. Schlag G, Redl H, Dinges HP, et al: Bacterial translocation in a baboon model of hypovolemic-traumatic shock. In Schlag G, Redl H, Siegel JH, et al, editors: Shock, sepsis and organ failure, Berlin, 1991, Springer.
  3. Deitch EA, Maejima K, Berg R: Effect of oral antibiotics and bacterial overgrowth on the translocation of the GI tract microflora in burned rats. J Trauma 25(5):385–392, 1985. PUBMED Abstract
  4. Deitch EA, Winterton J, Berg R: Effect of starvation, malnutrition, and trauma on the gastrointestinal tract flora and bacterial translocation. Arch Surg 122(9):1019–1024, 1987. PUBMED Abstract
  5. Baker B, Gaffin SL, Wells M, et al: Endotoxaemia in racehorses following exertion. J S Afr Vet Assoc 59(2):63–66, 1988. PUBMED Abstract
  6. Barton MH, Williamson L, Jacks S, et al: Effects on plasma endotoxin and eicosanoid concentrations and serum cytokine activities in horses competing in a 48-, 83-, or 159-km endurance ride under similar terrain and weather conditions. Am J Vet Res 64(6):754–761, 2003. PUBMED Abstract
  7. Hotchkiss RS, Coppersmith CM, Karl IE: Prevention of lymphocyte apoptosis-a potential treatment of sepsis. Clin Infect Dis 41(S7):S465–S469, 2005. PUBMED Abstract
  8. Castellheim A, Brekke OL, Espevik T, et al: Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis. Scand J Immunol 69:479–491, 2009. PUBMED Abstract
  9. Matzinger P: Tolerance, danger and the extended family. Annu Rev Immunol 12:991–1045, 1994. PUBMED Abstract
  10. Jack RS: Introduction: hunting devils. In Jack RS, editor: CD14 in the inflammatory response. Chem Immunol 74:1–4, 2000 (Basel, Karger). PUBMED Abstract
  11. Van Amersfoort ES, Van Berkel TJ, Kuiper J: Receptors, mediators and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev 16(3):379–414, 2003.
  12. Bentley AP, Barton MH, Lee MD, et al: Antimicrobial-induced endotoxin and cytokine activity in an in vitro model of septicemia in foals. Am J Vet Res 63(5):660–668, 2002. PUBMED Abstract
  13. MacKay RJ: Inflammation in horses. Vet Clin North Am Equine Pract 16(1):15–27, 2000. PUBMED Abstract
  14. Levy MM, Fink MP, Marshall JC, et al: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31(4):1250–1256, 2003. PUBMED Abstract
  15. Marshall JC, Reinhart K: Biomarkers of sepsis. Crit Care Med 37(7):2290–2298, 2009. PUBMED Abstract
  16. Barton MH, Collatos CL: Tumor necrosis factor and interleukin-6 activity and endotoxin concentration in peritoneal fluid and blood of horses with acute abdominal disease. J Vet Intern Med 13(5):457–464, 1999. PUBMED Abstract
  17. Steverink PJ, Sturk A, Rutten VP, et al: Endotoxin, interleukin-6 and tumor necrosis factor concentrations in equine acute abdominal disease: relation to clinical outcome. J Endotoxin Res 2:289–299, 1995.
  18. King JN, Gerring EL: Detection of endotoxin in cases of equine colic. Vet Rec 123(10):269–271, 1988. PUBMED Abstract
  19. Senior JM, Proudman CJ, Leuwer M, et al: Plasma endotoxin in horses presented to an equine referral hospital: correlation to selected clinical parameters and outcomes. Equine Vet J 43(5):585–591, 2011. PUBMED Abstract
  20. Barton MH, Morris DD, Norton N, et al: Hemostatic and fibrinolytic indices in neonatal foals with presumed septicemia. J Vet Intern Med 12(1):26–35, 1998. PUBMED Abstract
  21. Holmes CL, Russell JA, Walley KR: Genetic polymorphisms in sepsis and septic shock: role in prognosis and potential for therapy. Chest 124(3):1103–1115, 2003. PUBMED Abstract
  22. Arbour NC, Lorenz E, Schutte BC, et al: TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genetics 25:187–191, 2000. PUBMED Abstract
  23. Lorenz E, Mira JP, Frees KL, et al: Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 162:1028–1032, 2002. PUBMED Abstract
  24. Agnese DM, Calvano JE, Hahm SJ, et al: Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 186:1522–1525, 2002. PUBMED Abstract
  25. Lorenz E, Mira JP, Cornish KL, et al: A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun 68(11):6398–6401, 2000. PUBMED Abstract
  26. Rink L, Kirchner H: Recent progress in the tumor necrosis factor-alpha field. Int Arch Allergy Immunol 111:199–209, 1996. PUBMED Abstract
  27. Schluter B, Raufhake C, Erren M, et al: Effect of the interleukin-6 promoter polymorphism (2174 G/C) on the incidence and outcome of sepsis. Crit Care Med 30:32–37, 2002. PUBMED Abstract
  28. Lowe PR, Galley HF, Abdel-Fattah A, et al: Influence of interleukin-10 polymorphisms on interleukin-10 expression and survival in critically ill patients. Crit Care Med 31:34–38, 2003. PUBMED Abstract
  29. Shu Q, Fang X, Chen Q, et al: IL-10 polymorphism is associated with increased incidence of severe sepsis. Chin Med J (Engl) 116:1756–1759, 2003. PUBMED Abstract
  30. Schaaf BM, Boehmke F, Esnaashari H, et al: Pneumococcal septic shock is associated with the interleukin-10-1082 gene promoter polymorphism. Am J Respir Crit Care Med 168:476–480, 2003. PUBMED Abstract
  31. Matiasovic J, Lukeszova L, Horin P: Two bi-allelic single nucleotide polymorphisms within the promoter region of the horse tumour necrosis factor alpha gene. Eur J Immunogenetics 29:285–286, 2002. PUBMED Abstract
  32. Brown JJ, Ollier WER, Thomson W, et al: TNF-alpha haplotype frequencies in equidae. Tissue Antigens 67(5):377–382, 2006. PUBMED Abstract
  33. Horin P, Smola J, Matiasovic J, et al: Polymorphisms in equine immune response genes and their associations with infections. Mammalian Genome 15(10):843–850, 2004. PUBMED Abstract
  34. Werners AH, Bull S, Vendrig JC, et al: Genotyping of toll-like receptor 4, myeloid differentiation factor 2 and CD-14 in the horse: an investigation into the influence of genetic polymorphisms on the LPS induced TNF-alpha response in equine whole blood. Vet Immunol Immunopathol 111(3-4):165–173, 2006. PUBMED Abstract
  35. Tobias PS, Soldau K, Ulevitch RJ: Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum. J Exp Med 164(3):777–793, 1986. PUBMED Abstract
  36. Chow JC, Young DW, Golenbock DT, et al: Toll-like receptor 4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 274(16):10689–10692, 1999. PUBMED Abstract
  37. Frey EA, Miller DS, Jahr TG, et al: Soluble CD14 participates in the response of cells to lipopolysaccharide. J Exp Med 176(6):1665–1671, 1992. PUBMED Abstract
  38. Kak V: Mediators of systemic inflammatory response syndrome and the role of recombinant activated protein C in sepsis syndrome. Infect Dis Clin N Am 25:835–850, 2011. PUBMED Abstract
  39. Shimazu R, Akashi S, Ogata H, et al: MD-2, a molecule that confers lipopolysaccharide responsiveness on toll-like receptor 4. J Exp Med 189(11):1777–1782, 1999. PUBMED Abstract
  40. Van der Poll T, van Zoelen MAD, Wiersinga WJ: Regulation of pro- and anti-inflammatory host responses. In Herwald H, Egersten A, editors: Sepsis—pro-inflammatory and anti-inflammatory responses: good, bad or ugly? (contributions to Microbiology) Basel, 2011, Karger.
  41. Bone RC: Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 125(8):680–687, 1996. PUBMED Abstract
  42. Cavaillon JM, Annane D: Compartmentalization of the inflammatory response in sepsis and SIRS. J Endotoxin Res 12(3):151–170, 2006. PUBMED Abstract
  43. Munford RS, Pugin J: Normal response to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med 163:316–321, 2001. PUBMED Abstract
  44. Cavaillon JM: �Septic plasma�: an immunosuppressive milieu. Am J Respir Crit Care Med 166:1417–1418, 2002. PUBMED Abstract
  45. Muir WW: Shock. Comp Contin Educ Pract Vet 20(5):549–566, 1998.
  46. Levin M: The pathophysiology of overwhelming sepsis. In De Louvois J, Harvey D, editors: The inflammatory response to infection, New York, 1990, John Wiley & Sons.
  47. Barton MH: Endotoxemia. In White NA, Moore JN, editors: Current techniques in equine surgery and lameness, ed 2, Philadelphia, 1998, Saunders.
  48. Andonegui G, Goyert SM, Kubes P: Lipopolysaccharide-induced leukocyte-endothelial cell interactions: a role for CD14 versus toll-like receptor 4 within microvessels. J Immunol 169:2111–2119, 2002. PUBMED Abstract
  49. Abraham E: Neutrophils and acute lung injury. Crit Care Med 31(4):S195–S199, 2003. PUBMED Abstract
  50. Repine JE, Bowman CM, Tate RM: Neutrophils and lung oedema: state of the art. Am Rev Respir Dis 81:47–50, 1982.
  51. Henry MM, Moore JN: Whole blood re-calcification time in equine colic. Equine Vet J 23(4):303–308, 1991. PUBMED Abstract
  52. Johnstone IB, Crane S: Hemostatic abnormalities in equine colic. Am J Vet Res 47(2):356–358, 1986. PUBMED Abstract
  53. Prasse KW, Topper MJ, Moore JN: Analysis of hemostasis in horses with colic. J Am Vet Med Assoc 203(5):685–693, 1993. PUBMED Abstract
  54. Bentz AI, Palmer JE, Dallap BL, et al: Prospective evaluation of coagulation in critically ill neonatal foals. J Vet Intern Med 23(1):161–167, 2009. PUBMED Abstract
  55. Cotovio M, Monreal L, Armengou L, et al: Fibrin deposits and organ failure in newborn foals with severe septicemia. J Vet Intern Med 22(6):1403–1410, 2008. PUBMED Abstract
  56. Cotovio M, Monreal L, Navarro M, et al: Detection of fibrin deposits in tissues from horses with severe gastrointestinal disorders. J Vet Intern Med 21(2):308–313, 2007. PUBMED Abstract
  57. Henry MH, Moore JN: Clinical relevance of monocyte procoagulant activity in horses with colic. J Am Vet Med Assoc 198(5):843–848, 1991. PUBMED Abstract
  58. Barton MH, Collatos C, Moore JN: Endotoxin induced expression of tumour necrosis factor, tissue factor and plasminogen activator inhibitor activity by peritoneal macrophages. Equine Vet J 28(5):382–389, 1996. PUBMED Abstract
  59. Amaral A, Opal SM, Vincent JL: Coagulation in sepsis. Intensive Care Med 30:1032–1040, 2004. PUBMED Abstract
  60. Jarvis GE, Evans RJ: Endotoxin-induced platelet aggregation in heparinised equine whole blood in vitro. Res Vet Sci 57(3):317–324, 1994. PUBMED Abstract
  61. Jarvis GE, Evans RJ: Platelet-activating factor and not thromboxane A2 is an important mediator of endotoxin-induced platelet aggregation in equine heparinized whole blood in vitro. Blood Coagul Fibrinolysis 7(2):194–198, 1996. PUBMED Abstract
  62. Welles EG, Prasse KW, Moore JN: Use of newly developed assays for protein C and plasminogen in horses with signs of colic. Am J Vet Res 52(2):345–351, 1991. PUBMED Abstract
  63. Dellinger RP: Inflammation and coagulation: implications for the septic patient. Inflamm Coagul 36:1259–1265, 2003. PUBMED Abstract
  64. Collatos C, Barton MH, Schleef R, et al: Regulation of equine fibrinolysis in blood and peritoneal fluid based on a study of colic cases and induced endotoxaemia. Equine Vet J 26(6):474–481, 1994. PUBMED Abstract
  65. Collatos C, Barton MH, Prasse KW, et al: Intravascular and peritoneal coagulation and fibrinolysis in horses with acute gastrointestinal tract diseases. J Am Vet Med Assoc 207(4):465–470, 1995. PUBMED Abstract
  66. Morris DD: Recognition and management of disseminated intravascular coagulation in horses. Vet Clin North Am Equine Pract 4(1):115–143, 1988. PUBMED Abstract
  67. Opal SM: Phylogenetic and functional relationships between coagulation and the innate immune response. Crit Care Med 28:S77–S80, 2000. PUBMED Abstract
  68. Webster NR: Inflammation and the coagulation system. Br J Anaesth 89(2):216–220, 2002. PUBMED Abstract
  69. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709, 2001. PUBMED Abstract
  70. Mitka M: Drug for severe sepsis is withdrawn from market, fails to reduce mortality. JAMA 306(22):2439–2440, 2011. PUBMED Abstract
  71. Riedemann NC, Guo RF, Ward PA: The enigma of sepsis. J Clin Invest 112(4):460–467, 2003. PUBMED Abstract
  72. MacKay RJ: Treatment of endotoxemia and SIRS. In Proceedings of the 19th American College of Veterinary Internal Medicine Forum, Denver, 2001.
  73. Topper MJ, Prasse KW: Analysis of coagulation proteins as acute-phase reactants in horses with colic. Am J Vet Res 59(5):542–545, 1998. PUBMED Abstract
  74. Oliveira-Filho JP, Badial PR, Cunha PH, et al: Lipopolysaccharide infusion up-regulates hepcidin mRNA expression in equine liver. Innate Immun 18:438–446, 2012. PUBMED Abstract
  75. Welch RD, Watkins JP, Taylor TS, et al: Disseminated intravascular coagulation associated with colic in 23 horses (1984-1989). J Vet Intern Med 6:29–35, 1992. PUBMED Abstract
  76. Corley KT, Donaldson LL, Furr MO: Arterial lactate concentration, hospital survival, sepsis and SIRS in critically ill neonatal foals. Equine Vet J 37(1):53–59, 2005. PUBMED Abstract
  77. Furr M: Systemic inflammatory response syndrome, sepsis, and antimicrobial therapy. Clin Tech Equine Pract 2(1):3–8, 2003.
  78. Morris DD: Endotoxemia in horses: a review of cellular and humoral mediators involved in its pathogenesis. J Vet Intern Med 5(3):167–181, 1991. PUBMED Abstract
  79. Valentine BA, L�hr CV: Myonecrosis in three horses with colic: evidence for endotoxic injury. Vet Rec 161(23):786–789, 2007. PUBMED Abstract
  80. Nostell K, Br�jer J, H�glund K, et al: Cardiac troponin I and the occurrence of cardiac arrhythmias in horses with experimentally induced endotoxaemia. Vet J 192:171–175, 2012. PUBMED Abstract
  81. Slack JA, McGuirk SM, Erb, et al: Biochemical markers of cardiac injury in normal, surviving septic, or nonsurviving septic neonatal foals. J Vet Intern Med 19(4):577–580, 2005. PUBMED Abstract
  82. Daels PF, Stabenfeldt GH, Highes JP, et al: Evaluation of progesterone deficiency as a cause of fetal death in mares with experimentally induced endotoxemia. Am J Vet Res 52(2):282–288, 1991. PUBMED Abstract
  83. Daels PF, Stabenfeldt GH, Highes JP, et al: Effects of flunixin meglumine on endotoxin-induced prostaglandin F2 alpha secretion during early pregnancy in mares. Am J Vet Res 52(2):276–281, 1991. PUBMED Abstract
  84. Daoust DR, Orlowski SJ, McMahon G, et al: Limulus amebocyte lysate test as a method for detection of endotoxins and endotoxin-like materials. Bull Parenter Drug Assoc 30(1):13–20, 1976. PUBMED Abstract
  85. Peek SF, Borah S, Semrad S, et al: Plasma endotoxin concentration in horses: a methods study. Vet Clin Pathol 33:29–31, 2004. PUBMED Abstract
  86. Roth RI, Levin FC, Levin J: Optimization of detection of bacterial endotoxin in plasma with the limulus test. J Lab Clin Med 116:153–161, 1990. PUBMED Abstract
  87. Romaschin AD, Harris DM, Ribeiro MB, et al: A rapid assay of endotoxin in whole blood using autologous neutrophil dependent chemiluminescence. J Immunol Methods 212:169–185, 1998. PUBMED Abstract
  88. Koenig JB, Hart J, Harris DM, et al: Evaluation of endotoxin activity in blood measured via neutrophil chemiluminescence in healthy horses and horses with colic. Am J Vet Res 70(10):1183–1186, 2009. PUBMED Abstract
  89. Loisa P, Rinne T, Laine S, et al: Anti-inflammatory cytokine response and the development of multiple organ failure in severe sepsis. Acta Anaesthesiol Scand 47:319–325, 2003. PUBMED Abstract
  90. Morris DD, Moore JN: Tumor necrosis factor activity in serum from neonatal foals with presumed septicemia. J Am Vet Med Assoc 199(11):1584–1589, 1991. PUBMED Abstract
  91. MacKay RJ: Association between serum cytotoxicity and selected clinical variables in 240 horses admitted to a veterinary hospital. Am J Vet Res 53(5):748–752, 1992. PUBMED Abstract
  92. Gold JR, Perkins GA, Erb HN, et al: Cytokine profiles of peripheral blood mononuclear cells isolated from septic and healthy neonatal foals. J Vet Intern Med 21(3):482–488, 2007. PUBMED Abstract
  93. Pusterla N, Magdesian KG, Mapes S, et al: Expression of molecular markers in blood of neonatal foals with sepsis. Am J Vet Res 67:1045–1049, 2006. PUBMED Abstract
  94. Dellinger RP, Levy MM, Carlet JM, et al: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36:296–327, 2008. PUBMED Abstract
  95. Bradley SG: Cellular and molecular mechanisms of action of bacterial endotoxins. Annu Rev Microbiol 33:67–94, 1979. PUBMED Abstract
  96. Barton MH: Use of polymyxin B for treatment of endotoxemia in horses. Compr Contin Educ Equine Pract 11:1056–1059, 2000.
  97. Taniguchi T, Shibata K, Yamamoto K, et al: Effects of lidocaine administration on hemodynamics and cytokine responses to endotoxemia in rabbits. Crit Care Med 28(3):755–759, 2000. PUBMED Abstract
  98. Peir� JR, Barnab� PA, Cadioli FA, et al: Effects of lidocaine infusion during experimental endotoxemia in horses. J Vet Intern Med 24(4):940–948, 2010. PUBMED Abstract
  99. Rotting AK, Freeman DE, Constable PD, et al: Effects of phenylbutazone, indomethacin, prostaglandin E2, butyrate, and glutamine on restitution of oxidant-injured right dorsal colon of horses in vitro. Am J Vet Res 65(11):1589–1595, 2004. PUBMED Abstract
  100. Rotting AK, Freeman DE, Eurell JA, et al: Effects of acetylcysteine and migration of resident eosinophils in an in vitro model of mucosal injury and restitution in equine right dorsal colon. Am J Vet Res 64(10):1205–1212, 2003. PUBMED Abstract
  101. Boeckh A: Pharm profile: misoprostol. Compr Contin Educ Pract Vet 21:66–67, 1999.
  102. Sangiah S, MacAllister CC, Amouzadeh HR: Effects of misoprostol and omeprazole on basal gastric pH and free acid content in horses. Res Vet Sci 47(3):350–354, 1989. PUBMED Abstract
  103. Ziegler EJ, McCutchan JA, Fierer J, et al: Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 307(20):1225–1230, 1982. PUBMED Abstract
  104. Sakulramrung R, Domingue GJ: Cross-reactive immunoprotective antibodies to Escherichia coli O111 rough mutant J5. J Infect Dis 151(6):995–1004, 1985. PUBMED Abstract
  105. Wells MT, Gaffin SL, Gregory M, et al: Properties of equine anti-lipopolysaccharide hyperimmune plasma: binding to lipopolysaccharide and bactericidal activity against gram-negative bacteria. J Med Microbiol 24(3):187–196, 1987. PUBMED Abstract
  106. Sprouse RF, Garner HE, Lager K: Protection of ponies from heterologous and homologous endotoxin challenges via Salmonella typhimurium bacterin-toxoid. Equine Pract 11(2):34–40, 1989.
  107. Garner HE, Sprouse RF, Green EM: Active and passive immunization for blockade of endotoxemia. Proc Annu Meet Am Assoc Equine Pract 31, 1985.
  108. Morris DD, Whitlock RH: Therapy of suspected septicemia in neonatal foals using plasma containing antibodies to core lipopolysaccharide (LPS). J Vet Intern Med 1:175–182, 1987. PUBMED Abstract
  109. Garner HE, Sprouse RF, Lager K: Cross-protection of ponies from sublethal Escherichia coli endotoxemia by Salmonella typhimurium antiserum. Equine Pract 10(4):10–17, 1988.
  110. Spier SJ, Lavoie JP, Cullor JS, et al: Protection against clinical endotoxemia in horses by using plasma containing antibody to an Rc mutant E. coli (J5). Circ Shock 28(3):235–248, 1989. PUBMED Abstract
  111. Gaffin SL, Baker B, DuPrez J, et al: Prophylaxis and therapy with anti-endotoxin hyperimmune serum against gastroenteritis and endotoxemia in horses. Proc Annu Meet Am Assoc Equine Pract 28:335–340, 1982.
  112. Morris DD, Whitlock RH, Corbeil LB: Endotoxemia in horses: protection provided by antiserum to core lipopolysaccharide. Am J Vet Res 47(3):544–550, 1986. PUBMED Abstract
  113. Durando MM, MacKay RJ, Linda S, et al: Effects of polymyxin B and Salmonella typhimurium antiserum on horses given endotoxin intravenously. Am J Vet Res 55(7):921–927, 1994. PUBMED Abstract
  114. Parviainen AK, Barton MH, Norton NN: Evaluation of polymyxin B in an ex vivo model of endotoxemia in horses. Am J Vet Res 62(1):72–76, 2001. PUBMED Abstract
  115. Barton MH, Parviainen AK, Norton NN: Polymyxin B protects horses against induced endotoxemia in vivo. Equine Vet J 36(5):397–401, 2004. PUBMED Abstract
  116. Morresey PR, Mackay RJ: Endotoxin-neutralizing activity of polymyxin B in blood after IV administration in horses. Am J Vet Res 67(4):642–647, 2006. PUBMED Abstract
  117. Raisbeck MF, Garner HE, Osweiler GD: Effects of polymyxin B on selected features of equine carbohydrate overload. Vet Hum Toxicol 31:422–426, 1989. PUBMED Abstract
  118. Polymyxin B product information, Bedford, Ohio, 1999, Bedford Laboratories.
  119. MacKay RJ, Clark CK, Lodgeberg L, et al: Effect of a conjugate of polymyxin B-dextran 70 in horses with experimentally induced endotoxemia. Am J Vet Res 60:68–75, 1999. PUBMED Abstract
  120. Berlot G, Bacer B, Piva M, et al: Immunoglobulins in sepsis. Adv Sepsis 6(2):41–46, 2007.
  121. Reinhart K, Karzai W: Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med 29:S121–S125, 2001. PUBMED Abstract
  122. Fischer CJ, Dhainaut JF, Opal SM, et al: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra sepsis syndrome study group. JAMA 271:1836–1843, 1994. PUBMED Abstract
  123. Golenbock DT, Hampton RY, Qureshi N, et al: Lipid-A-like molecules that antagonize the effects of endotoxins on human monocytes. J Biol Chem 266(29):19490–19498, 1991. PUBMED Abstract
  124. Lien E, Means TK, Heine H, et al: Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest 105(4):497–504, 2000. PUBMED Abstract
  125. Akashi S, Nagai Y, Ogata H, et al: Human MD-2 confers on mouse toll-like receptor 4 species-specific lipopolysaccharide recognition. Int Immunol 13(12):1595–1599, 2001. PUBMED Abstract
  126. Muroi M, Ohnishi T, Tanamoto K: MD-2, a novel accessory molecule, is involved in species-specific actions of Salmonella lipid A. Infect Immunol 70(7):3546–3550, 2002. PUBMED Abstract
  127. Lohmann KL, Vandenplas ML, Barton MH, et al: The equine TLR4/MD-2 complex mediates recognition of lipopolysaccharide from Rhodobacter sphaeroides as an agonist. J Endotoxin Res 13(4):235–242, 2007. PUBMED Abstract
  128. Figueiredo MD, Moore JN, Vandenplas ML, et al: Effects of the second-generation synthetic lipid A analogue E5564 on responses to endotoxin in [corrected] equine whole blood and monocytes. Am J Vet Res 69(6):796–803, 2008. PUBMED Abstract
  129. Breuhaus BA, DeGraves FJ, Honore EK, et al: Pharmacokinetics of ibuprofen after intravenous and oral administration and assessment of safety of administration to healthy foals. Am J Vet Res 60(9):1066–1073, 1999. PUBMED Abstract
  130. Moore JN, Hardee MM, Hardee GE: Modulation of arachidonic acid metabolism in endotoxic horses: comparison of flunixin meglumine, phenylbutazone, and a selective thromboxane synthetase inhibitor. Am J Vet Res 47(1):110–113, 1986. PUBMED Abstract
  131. Jackman BR, Moore JN, Barton MH, et al: Comparison of the effects of ketoprofen and flunixin meglumine on the in vitro response of equine peripheral blood monocytes to bacterial endotoxin. Can J Vet Res 58:138–143, 1994. PUBMED Abstract
  132. MacKay RJ, Daniel CA, Bleyaert HF, et al: Effect of eltenac in horses with induced endotoxaemia. Equine Vet J Suppl 32:26–31, 2000. PUBMED Abstract
  133. Templeton CB, Bottoms GD, Fessler JF, et al: Endotoxin-induced hemodynamic and prostaglandin changes in ponies: effects of flunixin meglumine, dexamethasone, and prednisolone. Circ Shock 23:231–240, 1987. PUBMED Abstract
  134. Fessler JF, Bottoms GD, Roesel OF, et al: Endotoxin-induced change in hemograms, plasma enzymes, and blood chemical values in anesthetized ponies: effects of flunixin meglumine. Am J Vet Res 43(1):140–144, 1982. PUBMED Abstract
  135. Bottoms GD, Fessler JF, Roesel OF, et al: Endotoxin-induced hemodynamic changes in ponies: effects of flunixin meglumine. Am J Vet Res 42(9):1514–1518, 1981. PUBMED Abstract
  136. Moore JN, Garner HE, Shapland JE, et al: Prevention of endotoxin-induced arterial hypoxaemia and lactic acidosis with flunixin meglumine in the conscious pony. Equine Vet J 13(2):95–98, 1981. PUBMED Abstract
  137. Turek JJ, Templeton CB, Bottoms GD, et al: Flunixin meglumine attenuation of endotoxin-induced damage to the cardiopulmonary vascular endothelium of the pony. Am J Vet Res 46(3):591–596, 1985. PUBMED Abstract
  138. Templeton CB, Bottoms GD, Fessler JF, et al: Effects of repeated endotoxin injections on prostanoids, hemodynamics, endothelial cells, and survival in ponies. Circ Shock 16(3):253–264, 1985. PUBMED Abstract
  139. Semrad SD, Hardee GE, Hardee MM, et al: Low dose flunixin meglumine: effects on eicosanoid production and clinical signs induced by experimental endotoxaemia in horses. Equine Vet J 19(3):201–206, 1987. PUBMED Abstract
  140. Semrad SD, Moore JN: Effects of multiple low doses of flunixin meglumine on repeated endotoxin challenge in the horse. Prostaglandins Leukot Mediat 27:169–181, 1987. PUBMED Abstract
  141. Shuster R, Traub-Dargatz J, Baxter G: Survey of diplomates of the American College of Veterinary Internal Medicine and the American College of Veterinary Surgeons regarding clinical aspects and treatment of endotoxemia in horses. J Am Vet Med Assoc 210(1):87–92, 1997. PUBMED Abstract
  142. MacAllister CG, Morgan SJ, Borne AT, et al: Comparison of adverse effects of phenylbutazone, flunixin meglumine, and ketoprofen in horses. J Am Vet Med Assoc 202(1):71–77, 1993. PUBMED Abstract
  143. Keh D, Sprung CL: Use of corticosteroid therapy in patients with sepsis and septic shock: an evidence-based review. Crit Care Med 32(11):S527–S533, 2004. PUBMED Abstract
  144. Ewert KM, Fessler JF, Templeton CB, et al: Endotoxin-induced hematologic and blood chemical changes in ponies: effects of flunixin meglumine, dexamethasone and prednisolone. Am J Vet Res 46(1):24–30, 1985. PUBMED Abstract
  145. Morris DD, Moore JN, Crowe N, et al: Dexamethasone reduces endotoxin-induced tumor necrosis factor activity production in vitro by equine peritoneal macrophages. Cornell Vet 81(3):267–276, 1992.
  146. Hart KA, Slovis NM, Barton MH: Hypothalamic-pituitary-adrenal axis dysfunction in hospitalized neonatal foals. J Vet Intern Med 23:901–912, 2009. PUBMED Abstract
  147. Hart KA, Barton MH, Vandenplas ML, et al: Effects of low-dose hydrocortisone therapy on immune function in neonatal horses. Pediatr Res 70:72–77, 2011. PUBMED Abstract
  148. Arden WA, Slocombe RF, Stick JA, et al: Morphologic and ultrastructural evaluation of effect of ischemia and dimethyl sulfoxide on equine jejunum. Am J Vet Res 51(11):1784–1791, 1990. PUBMED Abstract
  149. Horne MM, Pascoe PJ, Ducharme NG, et al: Attempts to modify reperfusion injury of equine jejunal mucosa using dimethylsulfoxide, allopurinol, and intraluminal oxygen. Vet Surg 23(4):241–249, 1994. PUBMED Abstract
  150. Moore RM, Muir WW, Bertone AL, et al: Effects of dimethyl sulfoxide, allopurinol, 21-aminosteroid U-74389G, and manganese chloride on low-flow ischemia and reperfusion of the large colon in horses. Am J Vet Res 56(5):671–687, 1995. PUBMED Abstract
  151. Kelmer G, Doherty TJ, Elliott S, et al: Evaluation of dimethyl sulphoxide effects on initial response to endotoxin in the horse. Equine Vet J 40(4):358–363, 2008. PUBMED Abstract
  152. Kooreman K, Babbs C, Fessler J: Effect of ischemia and reperfusion on oxidative processes in the large colon and jejunum of horses. Am J Vet Res 59:340–346, 1998. PUBMED Abstract
  153. Weisiger RA: Oxygen radicals and ischemic tissue injury. Gastroenterology 90(2):494–496, 1986. PUBMED Abstract
  154. Lochner F, Sangiah S, Burrows G, et al: Effects of allopurinol in experimental endotoxin shock in horses. Res Vet Sci 47(2):178–184, 1989. PUBMED Abstract
  155. Carrick JB, Morris DD, Moore JN: Administration of a receptor antagonist for platelet-activating factor during equine endotoxaemia. Equine Vet J 25(2):152–157, 1993. PUBMED Abstract
  156. Cargile JL, MacKay RJ, Dankert JR, et al: Effect of treatment with a monoclonal antibody against equine tumor necrosis factor (TNF) on clinical, hematologic, and circulating TNF responses of miniature horses given endotoxin. Am J Vet Res 56(11):1451–1459, 1995. PUBMED Abstract
  157. Barton MH, Bruce EH, Moore JN, et al: Effect of tumor necrosis factor antibody given to horses during early experimentally induced endotoxemia. Am J Vet Res 59(6):792–797, 1998. PUBMED Abstract
  158. Barton MH, Moore JN: Pentoxifylline inhibits mediator synthesis in an equine in vitro whole blood model of endotoxemia. Circ Shock 44(4):216–220, 1994. PUBMED Abstract
  159. Barton MH, Moore JN, Norton N: Effects of pentoxifylline infusion on response of horses to in vivo challenge exposure with endotoxin. Am J Vet Res 58(11):1300–1307, 1997. PUBMED Abstract
  160. Baskett A, Barton MH, Norton N, et al: Effect of pentoxifylline, flunixin meglumine, and their combination on a model of endotoxemia in horses. Am J Vet Res 58(11):1291–1299, 1997. PUBMED Abstract
  161. Liska DA, Akucewich LH, Marsella R, et al: Pharmacokinetics of pentoxifylline and its 5-hydroxyhexyl metabolite after oral and intravenous administration of pentoxifylline to healthy adult horses. Am J Vet Res 67(9):1621–1627, 2006. PUBMED Abstract
  162. Kornreich B, Enyeart M, Jesty A, et al: The effects of pentoxifylline on equine platelet aggregation. J Vet Intern Med 24(5):1196–1202, 2010. PUBMED Abstract
  163. Bertone JJ, Gossett KA, Shoemaker KE, et al: Effect of hypertonic vs isotonic saline solution on responses to sublethal Escherichia coli endotoxemia in horses. Am J Vet Res 51(7):999–1007, 1990. PUBMED Abstract
  164. Toribio RE, Kohn CW, Hardy J, et al: Alterations in serum parathyroid hormone and electrolyte concentrations and urinary excretion of electrolytes in horses with induced endotoxemia. J Vet Intern Med 19(2):223–231, 2005. PUBMED Abstract
  165. Pantaleon LG, Furr MO, McKenzie HC, et al: Effects of small- and large-volume resuscitation on coagulation and electrolytes during experimental endotoxemia in anesthetized horses. J Vet Intern Med 21(6):1374–1379, 2007. PUBMED Abstract
  166. Cohen ND, Divers T: Acute colitis in horses. 2. Initial management. Compr Contin Educ Pract Vet 20:228–234, 1998.
  167. Jones PA, Bain FT, Byars TD, et al: Effect of hydroxyethyl starch infusion on colloid oncotic pressure in hypoproteinemic horses. J Am Vet Med Assoc 218(7):1130–1135, 2001. PUBMED Abstract
  168. MacFarlane D: Hetastarch: a synthetic colloid with potential in equine patients. Compr Contin Educ Pract Vet 21(9):867–877, 1999.
  169. Cohen ND, Divers T: Equine colitis. In Proceedings of the 15th American College of Veterinary Internal Medicine Forum, Lake Buena Vista, FL, 1997.
  170. Jones PA, Tomasic M, Gentry PA: Oncotic, hemodilutional, and hemostatic effects of isotonic saline and hydroxyethyl starch solutions in clinically normal ponies. Am J Vet Res 58(5):541–548, 1997. PUBMED Abstract
  171. Meister D, Hermann M, Mathis GA: Kinetics of hydroxyethyl starch in horses. Schweiz Arch Tierheilkd 134(7):329–333, 1992. PUBMED Abstract
  172. Pantaleon LG, Furr MO, McKenzie HC 2nd, et al: Cardiovascular and pulmonary effects of hetastarch plus hypertonic saline solutions during experimental endotoxemia in anesthetized horses. J Vet Intern Med 20(6):1422–1428, 2006. PUBMED Abstract
  173. Turkan H, Ural A, Beyan C, et al: Effects of hydroxyethyl starch on blood coagulation profile. Eur J Anaesthesiol 16(3):156–159, 1999. PUBMED Abstract
  174. Beale RJ, Hollenberg SM, Vincent JL, et al: Vasopressor and inotropic support in septic shock: an evidence-based review. Crit Care Med 32(11):S455–S465, 2004. PUBMED Abstract
  175. Corley KT, McKenzie HC, Amoroso LM, et al: Initial experience with norepinephrine infusion in hypotensive critically ill foals. J Vet Emerg Crit Care 10(4):267–276, 2000.
  176. Corley KTT: Inotropes and vasopressors in adults and foals. Vet Clin North Am Equine Pract 20:77–106, 2004.
  177. Wong DM, Brockus C, Alcott C, et al: Modifying the coagulation cascade: available medications. Compend Equine 4(5):224–236, 2009.
  178. Moore BR, Hinchcliff KW: Heparin: a review of its pharmacology and therapeutic use in horses. J Vet Intern Med 8(1):26–35, 1994. PUBMED Abstract
  179. Dallap BL: Coagulopathy in the equine critical care patient. Vet Clin North Am Equine Pract 20:231–251, 2004. PUBMED Abstract
  180. Monreal L, Villatoro AJ, Monreal M, et al: Comparison of the effects of low-molecular-weight and unfractionated heparin in horses. Am J Vet Res 56(10):1281–1285, 1995. PUBMED Abstract
  181. Schwarzwald C, Feige K, Wunderli-Allenspach H, et al: Comparison of pharmacokinetic variables for two low-molecular-weight heparins after subcutaneous administration of a single dose to horses. Am J Vet Res 63(6):868–873, 2002. PUBMED Abstract
  182. Armengou L, Monreal L, Delgado MA, et al: Low-molecular-weight heparin dosage in newborn foals. J Vet Intern Med 24(5):1190–1195, 2010. PUBMED Abstract
  183. Feige K, Schwarzwald CC, Bombeli T: Comparison of unfractioned and low molecular weight heparin for prophylaxis of coagulopathies in 52 horses with colic: a randomised double-blind clinical trial. Equine Vet J 35(5):506–513, 2003. PUBMED Abstract
  184. Broome TA, Brown MP, Gronwall RR, et al: Pharmacokinetics and plasma concentrations of acetylsalicylic acid after intravenous, rectal, and intragastric administration to horses. Can J Vet Res 67(4):297–302, 2003. PUBMED Abstract
  185. Hagedorn HW, Bock M, Schulz R: Acetylsalicylic acid and blood coagulation in the horse. Dtsch Tierarztl Wochenschr 99(10):410–412, 1992. PUBMED Abstract
  186. Brainard BM, Epstein KL, LoBato D, et al: Effects of clopidogrel and aspirin on platelet aggregation, thromboxane production, and serotonin secretion in horses. J Vet Intern Med 25(1):116–122, 2011. PUBMED Abstract
  187. Hattori Y, Takano K, Teramae H, et al: Insights into sepsis therapeutic design based on the apoptotic death pathway. J Pharmacol Sci 114:354–365, 2010 PUBMED Abstract
  188. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 348(2):138–150, 2003. PUBMED Abstract
  189. Hotchkiss RS, Tinsley KW, Karl IE: Role of apoptotic cell death in sepsis. Scand J Infect Dis 35:585–592, 2003. PUBMED Abstract
  190. Perl M, Chung CS, Perl U, et al: Fas-induced pulmonary apoptosis and inflammation during indirect acute lung injury. Am J Respir Crit Care Med 176:591–601, 2007. PUBMED Abstract
  191. Hotchkiss RS, Kevin W, Tinsley KW, et al: Endothelial cell apoptosis in sepsis. Crit Care Med 30:S225–S228, 2002. PUBMED Abstract
  192. Matsuda N, Hattori Y: Vascular biology in sepsis: pathophysiological and therapeutic significance of vascular function. J Smooth Muscle Res 43:117–137, 2007. PUBMED Abstract
  193. Voll RE, Hermann M, Roth EA, Stach C, et al: Immunosuppressive effects of apoptotic cells. Nature 390:350–351, 1997. PUBMED Abstract
  194. Fadok VA, Bratton DL, Konowal A, et al: Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 101:890–898, 1998. PUBMED Abstract
  195. Hask� G, Linden J, Cronstein B, et al: Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 7:759–770, 2008. PUBMED Abstract
  196. Sun WC, Berghaus LJ, Moore JN, et al: Lipopolysaccharide and TNF-alpha modify adenosine A(2A) receptor expression and function in equine monocytes. Vet Immunol Immunopathol 135(3-4):289–295, 2010. PUBMED Abstract
  197. Sun WC, Moore JN, Hurley DJ, et al: Differential modulation of lipopolysaccharide-induced expression of inflammatory genes in equine monocytes through activation of adenosine A2A receptors. Vet Immunol Immunopathol 134(3-4):169–177, 2010. PUBMED Abstract
  198. Sun WC, Moore JN, Hurley DJ, et al: Adenosine A2A receptor agonists inhibit lipopolysaccharide-induced production of tumor necrosis factor-alpha by equine monocytes. Vet Immunol Immunopathol 121(1-2):91–100, 2008. PUBMED Abstract
  199. Schroeder EL, Holcombe SJ, Cook VL, et al: Preliminary safety and biological efficacy studies of ethyl pyruvate in normal mature horses. Equine Vet J 43(3):341–347, 2011. PUBMED Abstract
  200. Cook VL, Holcombe SJ, Gandy JC, et al: Ethyl pyruvate decreases proinflammatory gene expression in lipopolysaccharide-stimulated equine monocytes. Vet Immunol Immunopathol 141(1-2):92–99, 2011. PUBMED Abstract
  201. Carrick JB, McCann ME: The effect of short-term administration of omega 3 fatty acids on endotoxemia. In Proceedings of the 15th American College of Veterinary Internal Medicine Forum, Lake Buena Vista, FL, 1997.
  202. Chu AJ, Walton MA, Prasad JK, et al: Blockade by polyunsaturated n-3 fatty acids of endotoxin-induced monocytic tissue factor activation is mediated by the depressed receptor expression in THP-1 cells. J Surg Res 87(2):217–222, 1999. PUBMED Abstract
  203. McCann ME, Moore JN, Carrick JB, et al: Effect of intravenous infusion of omega-3 and omega-6 lipid emulsions on equine monocyte fatty acid composition and inflammatory mediator production in vitro. Shock 14(2):222–228, 2000. PUBMED Abstract
  204. Morris DD, Henry MM, Moore JN, et al: Effect of dietary alpha-linolenic acid on endotoxin-induced production of tumor necrosis factor by peritoneal macrophages in horses. Am J Vet Res 52(4):528–532, 1991. PUBMED Abstract
  205. Henry MM, Moore JN, Feldman EB, et al: Effect of dietary alpha-linolenic acid on equine monocyte procoagulant activity and eicosanoid synthesis. Circ Shock 32(3):173–188, 1990. PUBMED Abstract
  206. Henry MM, Moore JN, Fischer JK: Influence of an omega-3 fatty acid–enriched ration on in vivo responses of horses to endotoxin. Am J Vet Res 52(4):523–527, 1991. PUBMED Abstract
  207. Moore JN, Norton N, Barton MH, et al: Rapid infusion of a phospholipid emulsion attenuates the effects of endotoxaemia in horses. Equine Vet J 39(3):243–248, 2007. PUBMED Abstract
  208. Winchell WW, Hardy J, Levine DM, et al: Effect of administration of a phospholipid emulsion on the initial response of horses administered endotoxin. Am J Vet Res 63:1370–1378, 2002. PUBMED Abstract